Ned Sharpless. NCI

Sharp­less out­lines FDA’s key pri­or­i­ties for ad­vanc­ing pub­lic health

Four months in­to his tenure, Act­ing FDA Com­mis­sion­er Ned Sharp­less sent an email to FDA staff on Tues­day out­lin­ing four main pri­or­i­ty ar­eas: as­sur­ing pub­lic health through emerg­ing tech­nolo­gies, in­vest­ing in the FDA’s next gen­er­a­tion ex­pert work­force and in­fra­struc­ture, mod­ern­iz­ing frame­works and pro­mot­ing and pro­tect­ing con­sumer and pa­tient safe­ty.

On the emerg­ing tech­nolo­gies front, Sharp­less dis­cussed how the FDA is try­ing to stay ahead of the curve while en­cour­ag­ing in­dus­try to adopt less cost­ly and more re­li­able ad­vanced man­u­fac­tur­ing plat­forms.

“We see the promise of tech­nolo­gies like 3D-print­ed de­vices, cell-cul­tured food, cell-based ther­a­peu­tics, and in­ten­tion­al ge­nom­ic al­ter­ations to an­i­mals and plants to de­liv­er enor­mous ben­e­fits to pub­lic health. As these fas­ci­nat­ing tech­nolo­gies are de­vel­oped, how­ev­er, the FDA will al­so need to aug­ment its ex­per­tise in these ar­eas to af­ford op­ti­mal re­view and reg­u­la­tion of prod­ucts de­rived from cut­ting-edge tech­nol­o­gy,” he wrote.

Sharp­less al­so de­clared hir­ing as an “im­me­di­ate pri­or­i­ty,” as oth­er of­fi­cials have lament­ed the gaps in the FDA’s work­force.

“We will be de­ploy­ing the 21st Cen­tu­ry Cures hir­ing au­thor­i­ty at much greater scale. Sim­ply put, we need to re­cruit, de­vel­op, and re­tain world- class peo­ple, and will be an­nounc­ing more spe­cif­ic plans in these ar­eas soon,” he wrote.

On mod­ern­iz­ing frame­works, Sharp­less touched on the FDA’s work to speed gener­ic drugs and biosim­i­lars to mar­ket to low­er drug prices and not­ed work to try to help in­dus­try with “the most ex­pen­sive part of drug dis­cov­ery and de­vel­op­ment,” which is the clin­i­cal test­ing.

“To ex­pe­dite de­vel­op­ment of ef­fec­tive ther­a­peu­tics and di­ag­nos­tics, we will con­tin­ue to pro­mote the use of in­no­v­a­tive clin­i­cal tri­al de­signs such as plat­form tri­als, bas­ket stud­ies, adap­tive tri­als, and prag­mat­ic ran­dom­ized con­trolled tri­als that are more ef­fi­cient and will low­er costs of run­ning tri­als,” he wrote.

Re­al-world ev­i­dence, a top­ic dis­cussed last week at an FDA event, will al­so help with pre- and post­mar­ket ad­verse event de­tec­tion and ef­fi­ca­cy analy­ses for clin­i­cal sit­u­a­tions where ran­dom­ized clin­i­cal tri­als may not be fea­si­ble.

“En­hanced use of re­al-world ev­i­dence for reg­u­la­to­ry de­ci­sion mak­ing will im­prove the gen­er­al­iz­abil­i­ty of ev­i­dence to pa­tient pop­u­la­tions that may be ex­clud­ed from tra­di­tion­al clin­i­cal tri­als,” he added.

As far as pa­tient safe­ty, Sharp­less re­it­er­at­ed the FDA’s in­ter­est in strength­en­ing post-mar­ket sur­veil­lance.

“For in­stance, nov­el ma­chine learn­ing al­go­rithms can al­low us to pri­or­i­tize in­ter­na­tion­al mail in­spec­tions to bet­ter de­tect il­lic­it opi­oid ship­ments; blockchain can help us track and trace food out­breaks with greater speed; and aug­ment­ed track and trace tech­nolo­gies can help us im­prove the safe­ty of drugs, de­vices, and vet­eri­nary prod­ucts,” he wrote.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

FDA to Sarep­ta: Your wide­ly an­tic­i­pat­ed fol­lowup to Ex­ondys 51 is not get­ting an ac­cel­er­at­ed OK for Duchenne MD

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.
SpringWorks

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.